{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-012218","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.170716+00:00","generated_at":"2026-06-24T04:05:59.095318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Biostage reports Q2 2022 net loss of $1.3M; raises $5.1M in private placement","bullets":["Net loss of $1.3M ($0.12 per share) vs $0.4M loss in Q2 2021; increase due to higher legal costs and prior-year PPP loan forgiveness.","Completed private placement in May 2022, generating net proceeds of ~$5.1M to fund clinical development of Biostage Esophageal Implant (BEI).","Operating cash on-hand of $4.6M as of June 30, 2022; expected runway into Q2 2023.","Executed settlement with Harvard Bioscience and plaintiffs in wrongful death litigation; no admission of liability."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-012218","json":"https://secwatch.observer/filing/0001558370-22-012218.json","markdown":"https://secwatch.observer/filing/0001558370-22-012218.md","text":"https://secwatch.observer/filing/0001558370-22-012218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000155837022012218/0001558370-22-012218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000155837022012218/tmb-20220804x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:05:59.095318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}